# US 2008/0305147 A1 · Drug Delivery System For The Prevention Of Cerebral Vasospasm

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305147 A1
- Document ID: US20080305147A1
- Status: Published application
- Kind: A1
- Application number: 12/137,320
- Filed: 2008-06-11
- Published: 2008-12-11
- Earliest claimed: 2007-06-11
- Assignees: Edge Therapeutics, Inc.
- Inventors: R. Loch Macdonald; Brian Leuthner
- Web page: https://patentgrep.com/patent/US20080305147A1

## CPC

- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm.

## Claims

### Claim 1

A method of treating a cerebral vasospasm in a human, the method comprising the steps:
a) providing a pharmaceutical composition;
b) administering a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space;
c) wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises a therapeutic agent and pharmaceutical carrier.

### Claim 3 (depends on 2)

The method of claim 2, wherein the therapeutic agent is a calcium channel blocker.

### Claim 4 (depends on 2)

The method of claim 2, wherein the therapeutic agent is a calcium channel antagonist.

### Claim 5 (depends on 2)

The method of claim 2, wherein the therapeutic agent is a calcium channel inhibitor.

### Claim 6 (depends on 2)

The method of claim 2, wherein the therapeutic agent is a transient receptor potential protein blocker.

### Claim 7 (depends on 2)

The method of claim 2, wherein the therapeutic agent is an endothelin receptor antagonist.

### Claim 8 (depends on 2)

The method of claim 2, wherein the carrier is a gel compound.

### Claim 9 (depends on 2)

The method of claim 2, wherein the carrier is a semisolid compound.

### Claim 10 (depends on 2)

The method of claim 2, wherein the carrier is a slow-release solid compound.

### Claim 11 (depends on 2)

The method of claim 2, wherein the therapeutic agent is selected from the group consisting of amlodipine, aranidipine, azelnidipine, bamidipine, benidipine, bepridil, cinaldipine, diltiazem, efonidipine, felodipine, gallopamil, isradipine, lacidipine, lemildipine, lercanidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, manidipine, pranidipine, verapamil or a combination thereof.

### Claim 12 (depends on 2)

The method of claim 2, wherein the therapeutic agent is selected from the group consisting of A-127722, ABT-627, BMS 182874, BQ-123, BQ-153, BQ-162, BQ-485, BQ-518, BQ-610, EMD-122946, FR 139317, IPI-725, L-744453, LU 127043, LU 135252, PABSA, PD 147953, PD 151242, PD 155080, PD 156707, RO 611790, SB-247083, clazosentan, atrasentan, sitaxsentan sodium, TA-0201, TBC 11251, TTA-386, WS-7338B, ZD-1611, aspirin, A-182086, CGS 27830, CP 170687, J-104132, L-751281, L-754142, LU 224332, LU 302872, PD 142893, PD 145065, PD 160672, RO-470203, bosentan, RO 462005, RO 470203, SB 209670, SB 217242, TAK-044, A-192621, A-308165, BQ-788, BQ-017, IRL 1038, IRL 2500, PD-161721, RES 701-1, and RO 468443.

### Claim 13 (depends on 2)

The method of claim 2, wherein the therapeutic agent is selected from the group consisting of SKF 96365 and LOE 908.

### Claim 14 (depends on 1)

The method of claim 1, wherein the predetermined location in step (b) is from about 05 mm to about 10 mm from a cerebral artery.

### Claim 15 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered by implantation.

### Claim 16 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered by surgical injection.

### Claim 17

A method of treating a human for vasospasm after subarachnoid hemorrhage in at least one cerebral artery, the method comprising the steps of:
a) providing a pharmaceutical composition;
b) administering a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space;
c) wherein the pharmaceutical composition produces a localized therapeutic effect thereby treating the vasospasm.

### Claim 18 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition comprises a therapeutic agent and pharmaceutical carrier.

### Claim 19 (depends on 18)

The method of claim 18, wherein the therapeutic agent is a calcium channel blocker.

### Claim 20 (depends on 18)

The method of claim 18, wherein the therapeutic agent is a calcium channel antagonist.

### Claim 21 (depends on 18)

The method of claim 18, wherein the therapeutic agent is a calcium channel inhibitor.

### Claim 22 (depends on 182)

The method of claim 182, wherein the therapeutic agent is a transient receptor potential protein blocker.

### Claim 23 (depends on 18)

The method of claim 18, wherein the therapeutic agent is an endothelin receptor antagonist.

### Claim 24 (depends on 18)

The method of claim 18, wherein the carrier is a gel compound.

### Claim 25 (depends on 18)

The method of claim 18, wherein the carrier is a semisolid compound.

### Claim 26 (depends on 18)

The method of claim 18, wherein the carrier is a slow-release solid compound.

### Claim 27 (depends on 18)

The method of claim 18, wherein the therapeutic agent is selected from the group consisting of amlodipine, aranidipine, azelnidipine, bamidipine, benidipine, bepridil, cinaldipine, diltiazem, efonidipine, felodipine, gallopamil, isradipine, lacidipine, lemildipine, lercanidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, manidipine, pranidipine, verapamil or a combination thereof.

### Claim 28 (depends on 18)

The method of claim 18, wherein the therapeutic agent is selected from the group consisting of A-127722, ABT-627, BMS 182874, BQ-123, BQ-153, BQ-162, BQ-485, BQ-518, BQ-610, EMD-122946, FR 139317, IPI-725, L-744453, LU 127043, LU 135252, PABSA, PD 147953, PD 151242, PD 155080, PD 156707, RO 611790, SB-247083, clazosentan, atrasentan, sitaxsentan sodium, TA-0201, TBC 11251, TTA-386, WS-7338B, ZD-1611, aspirin, A-182086, CGS 27830, CP 170687, J-104132, L-751281, L-754142, LU 224332, LU 302872, PD 142893, PD 145065, PD 160672, RO-470203, bosentan, RO 462005, RO 470203, SB 209670, SB 217242, TAK-044, A-192621, A-308165, BQ-788, BQ-017, IRL 1038, IRL 2500, PD-161721, RES 701-1, and RO 468443.

### Claim 29 (depends on 18)

The method of claim 18, wherein the therapeutic agent is selected from the group consisting of SKF 96365 and LOE 908.

### Claim 30 (depends on 17)

The method of claim 17, wherein the predetermined location in step (b) is from 0 about 5 mm to about 10 mm from a cerebral artery.

### Claim 31 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition is administered by implantation.

### Claim 32 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition is administered by surgical injection.

### Claim 33

A pharmaceutical composition for administration into the subarachnoid space for treating cerebral vasospasm in a human comprising
a) a therapeutically effective amount of a therapeutic agent; and
b) a pharmaceutical carrier.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, wherein the therapeutic agent is selected from the group consisting of amlodipine, aranidipine, azelnidipine, bamidipine, benidipine, bepridil, cinaldipine, diltiazem, efonidipine, felodipine, gallopamil, isradipine, lacidipine, lemildipine, lercanidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, manidipine, pranidipine, verapamil, A-127722, ABT-627, BMS 182874, BQ-123, BQ-153, BQ-162, BQ-485, BQ-518, BQ-610, EMD-122946, FR 139317, IPI-725, L-744453, LU 127043, LU 135252, PABSA, PD 147953, PD 151242, PD 155080, PD 156707, RO 611790, SB-247083, clazosentan, atrasentan, sitaxsentan sodium, TA-0201, TBC 11251, TTA-386, WS-7338B, ZD-1611, aspirin, A-182086, CGS 27830, CP 170687, J-104132, L-751281, L-754142, LU 224332, LU 302872, PD 142893, PD 145065, PD 160672, RO-470203, bosentan, RO 462005, RO 470203, SB 209670, SB 217242, TAK-044, A-192621, A-308165, BQ-788, BQ-017, IRL 1038, IRL 2500, PD-161721, RES 701-1, RO 468443, SKF 96365 and LOE 908.

### Claim 35 (depends on 33)

The pharmaceutical composition of claim 33, wherein the therapeutic agent is a calcium channel blocker.

### Claim 36 (depends on 33)

The pharmaceutical composition of claim 33, wherein the therapeutic agent is a calcium channel antagonist.

### Claim 37 (depends on 33)

The pharmaceutical composition of claim 33, wherein the therapeutic agent is a calcium channel inhibitor.

### Claim 38 (depends on 33)

The pharmaceutical composition of claim 33, wherein the therapeutic agent is a transient receptor potential protein blocker.

### Claim 39 (depends on 33)

The pharmaceutical composition of claim 33, wherein the therapeutic agent is an endothelin receptor antagonist.

### Claim 40 (depends on 33)

The pharmaceutical composition of claim 33, wherein the pharmaceutical carrier is a gel compound.

### Claim 41 (depends on 33)

The pharmaceutical composition of claim 33, wherein the pharmaceutical carrier is a slow-release solid compound.

### Claim 42 (depends on 33)

The pharmaceutical composition of claim 33, wherein the pharmaceutical carrier is a semisolid compound.
